These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11573324)

  • 21. [Management of community-acquired lower respiratory infections. Management in the hospital].
    Chidiac C
    Rev Mal Respir; 1999 Jan; 16 Suppl 3():S11-2. PubMed ID: 10088221
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
    Talan DA
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S64-71. PubMed ID: 11249831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Recent fluoroquinolones. Highly effective weapons for ambulatory therapy].
    Stahlmann R; Lode H
    MMW Fortschr Med; 1999 Nov; 141(47):35-6. PubMed ID: 10912165
    [No Abstract]   [Full Text] [Related]  

  • 24. Novel agents for the treatment of outpatient respiratory tract infections. Introduction.
    Pell DM
    Postgrad Med; 2002 Sep; 112(3 Suppl):5-6. PubMed ID: 19667592
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of adults with community-acquired respiratory tract infections: results of a multicentric clinical trial with gatifloxacin.
    Medeiros EA
    Braz J Infect Dis; 2002 Aug; 6(4):149-56. PubMed ID: 12204181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Geminofloxacin for the management of community-acquired respiratory tract infections.
    Blondeau JM; Tillotson G; Deangelis J
    J Chemother; 2006 Dec; 18(6):582-8. PubMed ID: 17267335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Moxifloxacin--a novel antimicrobial preparation for treatment of respiratory infections].
    Iakovlev SV; Polushkina NR; Iakovlev VP
    Ter Arkh; 2001; 73(11):15-22. PubMed ID: 11806197
    [No Abstract]   [Full Text] [Related]  

  • 28. Antimicrobial drug use and resistance among respiratory pathogens in the community.
    Low DE
    Clin Infect Dis; 2001 Sep; 33 Suppl 3():S206-13. PubMed ID: 11524720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment?
    Norrby SR
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():99-101. PubMed ID: 9484879
    [No Abstract]   [Full Text] [Related]  

  • 31. Fluoroquinolones for respiratory infections: too valuable to overuse.
    Williams JH
    Chest; 2001 Dec; 120(6):1771-5. PubMed ID: 11742900
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.
    Ambrose PG; Grasela DM; Grasela TH; Passarell J; Mayer HB; Pierce PF
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2793-7. PubMed ID: 11557471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New antibiotic approved for community-acquired infections.
    Nurse Pract; 1998 Jan; 23(1):94. PubMed ID: 9470200
    [No Abstract]   [Full Text] [Related]  

  • 34. New antibiotics for community-acquired lower respiratory tract infections: improved activity at a cost?
    Ball P
    Int J Antimicrob Agents; 2000 Nov; 16(3):263-72. PubMed ID: 11091046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections.
    Blondeau JM
    Expert Opin Investig Drugs; 2001 Feb; 10(2):213-37. PubMed ID: 11178338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The role of quinolones in the treatment of community acquired pneumonia].
    Garau J
    Med Clin (Barc); 1998 Feb; 110 Suppl 1():31-5. PubMed ID: 9717158
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug not considered a first-line agent.
    Lexchin J
    Can Fam Physician; 1998 Nov; 44():2376. PubMed ID: 9839049
    [No Abstract]   [Full Text] [Related]  

  • 38. [Other communal respiratory pathogens and new fluoroquinolones].
    Cantón R; Loza E; Valdezate S; Baquero F
    Enferm Infecc Microbiol Clin; 1998 Dec; 16 Suppl 2():12-21; discussion 47-52. PubMed ID: 10344094
    [No Abstract]   [Full Text] [Related]  

  • 39. A placebo controlled evaluation of lomefloxacin in the treatment of bacterial diarrhoea in the community.
    Ellis-Pegler RB; Hyman LK; Ingram RJ; McCarthy M
    J Antimicrob Chemother; 1995 Jul; 36(1):259-63. PubMed ID: 8537277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pathogens isolated from patients with community-acquired lower respiratory tract infections].
    Kiryszewska A; Antczak A
    Med Dosw Mikrobiol; 2011; 63(4):333-9. PubMed ID: 22384667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.